Guggenheim Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Brad Canino initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $8.
Guggenheim analyst Brad Canino initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $8.